Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease

被引：0
|
作者：
Andrew P. Yu
Scott Johnson
Si-Tien Wang
Pavel Atanasov
Jackson Tang
Eric Wu
Jingdong Chao
Parvez M. Mulani
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Abbott Laboratories,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Infliximab; Adalimumab; Probabilistic Sensitivity Analysis; Tumour Necrosis Factor Antagonist; Infliximab Maintenance Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease.
引用
收藏
页码：609 / 621
页数：12
相关论文
共 50 条
  • [21] Adalimumab maintains long-term remission in moderately to severely active Crohn's disease through 2 years
    Panaccione, Remo
    Colombel, Jean-Frederic
    Sandbom, William J.
    Rutgeens, Paul
    D'Haens, Geert
    Lomax, Kathleen G.
    Li, Ju
    Wong, Robert
    Pollack, Paul F.
    GASTROENTEROLOGY, 2008, 134 (04) : A134 - A134
  • [22] Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis
    Toor, Kabirraaj
    Druyts, Eric
    Jansen, Jeroen P.
    Thorlund, Kristian
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (06) : 437 - 446
  • [23] Impact of infliximab history on the efficacy of adalimumab in patients with moderately to severely active luminal and/or fistulizing Crohn's disease -: Week 4 results of an open-label study
    Hinojosa, Joaquin
    Gomollon, F.
    Ricart, E.
    Minguez, M.
    Calderon, R.
    Barreiro, F.
    Gassull, M. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S456 - S456
  • [24] Long-term results of adalimumab treatment in subjects with moderately to severely active fistulizing Crohn's disease who have failed response or showed intolerance to infliximab
    Gomollon, F.
    Hinojosa, J.
    Nos, P.
    Penate, M.
    Ceballos, D.
    Gassull, M. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S496 - S496
  • [25] A retrospective comparison of infliximab versus adalimumab as induction therapy for crohn's disease
    Varma, P.
    Huang, C.
    Paul, E.
    Headon, B.
    Sparrow, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 108 - 109
  • [26] COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Schultz, Robert
    Diakite, Ibrahim
    Carter, John A.
    Snedecor, Sonya
    Turpin, Robin S.
    GASTROENTEROLOGY, 2020, 158 (06) : S658 - S658
  • [27] Improvement in Markers of Bone Metabolism with Adalimumab in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1
    Griffiths, Anne
    Baldassano, Robert
    Bronsky, Jiri
    Hyams, Jeffrey
    Lazar, Andreas
    Wang, Yaqin
    Eichner, Samantha
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S622 - S622
  • [28] Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Sandborn, William J.
    Rutgeerts, Paul
    Geboes, Karel
    Petersson, Joel
    Eichner, Samantha
    Zhou, Qian
    Robinson, Anne M.
    Read, Holly A.
    Thakkar, Roopal
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (04): : 425 - 434
  • [29] Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1
    Ruemmele, Frank
    Rosh, Joel
    Colletti, Richard
    Faubion, William
    Markowitz, James
    Eichner, Samantha
    Wang, Yaqin
    Lazar, Andreas
    Thakkar, Roopal
    Hyams, Jeffrey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S623 - S624
  • [30] Maintenance therapy versus episodic therapy with infliximab for Crohn's disease
    Ghosh, Subrata
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 80 - 81
12345